Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan

Yanagi, Yasuo; Takahashi, Kanji; Iida, Tomohiro; Gomi, Fumi; Morii, J.; Kunikane, Eriko; Sakamoto, Taiji

doi:10.1007/s40123-023-00715-y

Cited by 6 publications

(1 citation statement)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study evaluating anti-VEGF therapies for nAMD, the focus was on the cost-effectiveness of the ranibizumab biosimilar from a Japanese societal perspective. 39 Using a Markov model, the study compared ranibizumab biosimilar with branded ranibizumab, aflibercept, and their combinations in treat-and-extend (TAE) and pro re nata (PRN) regimens, as well as against best supportive care (BSC).…”

Section: Cost Effectivenessmentioning

confidence: 99%

Ranibizumab Biosimilars in Treating Retinal Disorders: A Cost-Effective Revolution?

Chatzimichail,

Pfau,

Gatzioufas

et al. 2024

DDDT

View full text Add to dashboard Cite

Ranibizumab, is a humanized, monoclonal antibody fragment that binds and inactivates vascular endothelial growth factor-A (VEGF-A) and VEGF-B. One of the main indications for an intravitreal treatment with ranibizumab is age-related macular degeneration (AMD), which is a retinal disease with a high worldwide socioeconomic impact. Biosimilars constitute biological products that demonstrate similar pharmacodynamic and pharmacokinetic characteristics with a reference product, as well as comparable clinical efficacy, safety and immunogenicity. Since the approval of the first biosimilar Razumab, there has been a variety of new biosimilars available on the market. They offer the advantage of the same good clinical and safety results at a better price. All Ranibizumab biosimilars that have gained approval were tested in double masked Phase 3 clinical studies. The use of Ranibizumab biosimilars in neovascular AMD is well reported in the bibliography. Nevertheless, over the last few years, there is a tendency of using biosimilars in other retinal diseases like retinopathy of prematurity (ROP), diabetic macular edema (DME) or polypoidal choroidal vasculopathy (PCV). In conclusion, ranibizumab biosimilars offer a promising avenue for the management of retinal diseases, especially in countries with lower socioeconomic status, where there is lack of availability of innovator ranibizumab. However, further research is required to fully explore their efficacy, safety, and long-term outcomes in a plethora of retinal diseases.

show abstract

Section: Cost Effectivenessmentioning

confidence: 99%